No­var­tis buys Mallinck­rodt's FDA vouch­er for $100M but re­mains mum on where to use its 7th PRV

No­var­tis on Thurs­day con­firmed to End­points News that it pur­chased a pri­or­i­ty re­view vouch­er from bank­rupt phar­ma com­pa­ny Mallinck­rodt, but the Swiss-Amer­i­can multi­na­tion­al com­pa­ny de­clined to elab­o­rate on how it plans to use its sev­enth PRV.

Un­der the terms of the deal, PRV mar­ket leader No­var­tis agreed to pay $65 mil­lion to Mallinck­rodt and $35 mil­lion to a trust as part of the com­pa­ny’s court-ap­proved bank­rupt­cy deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER